Do you want to skip to content? Skip to content
Contact Us Convatec.com Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
False /oidc-signin/en-us/ Contact Us Convatec.com Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本

Comment on proposed draft Local Coverage Determinations (LCDs) on skin substitutes

London, April 26th 2024

Convatec notes the start of a forty-five day public consultation period with respect to the newly proposed draft Local Coverage Determinations (LCDs) “Skin Substitute Grafts / Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers”.

As we have previously noted, the reimbursement environment in this segment is dynamic. Last year, a similar process resulted in no change in coverage. This is the beginning of a new LCD process and there is no certainty as to the timing or outcomes that may or may not result.

Convatec will actively engage with all relevant parties over the course of the consultation period. We seek an outcome that preserves choice for clinicians treating chronic wounds and is in the best interest of patients.

We are confident in the clinical efficacy of our InnovaMatrix® platform and continue to build our clinical evidence portfolio. Clinicians and patients have experienced first-hand the positive impact InnovaMatrix® products have on chronic wounds.

Contacts

Analysts & Investors

Kate Postans, Vice President of Investor Relations & Treasury

+44 (0) 7826 447807

 

Sheebani Chothani, Director of Investor Relations

+44 (0) 7805 011046
ir@convatec.com

Media

Buchanan: Charles Ryland / Chris Lane

+44 (0)207 466 5000

 

 

 

 

Press Release

See all

16-May-24

Corporate

Financial Performance

logo, company name

AGM trading update for the four months ended 30 April 2024

Revenue continued to build, further strategic progress, on track to deliver financial guidance

Read more

01-May-24

Advanced Wound Care

text, application, Word

Convatec unveils significant advanced wound care clinical study results

New research demonstrates superiority of AQUACEL® Ag+ Extra™ dressing in the management of venous leg ulcers

Read more

26-Apr-24

Corporate

logo, company name

Comment on proposed draft Local Coverage Determinations (LCDs) on skin substitutes

Read more

06-Mar-24

Corporate

Financial Performance

logo, company name

Annual Results for the twelve months ended 31 December 2023

Read more

29-Feb-24

Ostomy Care

a woman holding a shoe

Convatec launches new Esteem Body™ with Leak Defense™

Read more

11-Jan-24

Infusion Care

icon

Convatec expands support for people living with advanced Parkinson´s disease

Read more